Scientific Publication on Global Rubella

2023

Progress Toward Measles and Rubella Elimination – Indonesia, 2013-2022.
Chacko S, Kamal M, Endang, BH et al. MMWR Morb Mortal Wkly Rep. 2023:72:1134-1139. doi: 10.15585/mmwr.mm7242a2

Estimates of the global burden of Congenital Rubella Syndrome, 1996-2019.
Vynnycky E, Knapp JK, Papadopoulos T, et al. Int J Infect Dis. 2023. S1201-9712(23)00715-4. doi: 10.1016/j.ijid.2023.09.003. Epub ahead of print.

Nationwide measles and rubella outbreaks in South Sudan, 2019.
Peck ME, Maleghemi S, Kayembe L, et al. Open Forum Infect Dis. 2023;10(2):ofad032.

2022

How Australia's measles control activities have catalyzed rubella elimination.
Glynn-Robinson A, Knapp JK, Durrheim DN. International Journal of Infectious Diseases. 2022;114:72-78. doi: 10.1016/j.ijid.2021.11.003.

Feasibility of measles and rubella vaccination programmes for disease elimination: A modelling study.
Winter AK, Lambert B, Klein D, et al. Lancet Glob Health. 2022;10(10):E1412-E1422. doi: 10.1016/S2214-109X(22)00335-7.

Progress toward rubella and congenital rubella syndrome control and elimination — Worldwide, 2012-2020.
Zimmerman LA, Knapp JK, Antoni S, Grant GB, and Reef SE. MMWR Morb Mortal Wkly Rep. 2022;71(6):196-201. doi: 10.15585/mmwr.mm7106a2.

2021

Feasibility assessment of measles and rubella eradication.
Moss WJ, Shendale S, Lindstrand A, et al. Vaccine. 2021;39(27):3544-3559. doi: 10.1016/j.vaccine.2021.04.027.

Progress toward rubella elimination — World Health Organization European Region, 2005–2019.
O’Connor P, Yankovic D, Zimmerman L, Ben Mamou M, Reef S. MMWR Morb Mortal Wkly Rep. 2021;70:833–839. doi: 10.15585/mmwr.mm7023a1.

Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: A metapopulation modelling study.
Su Q, Feng Z, Hao L, et al. Lancet Infect Dis. 2021;21(7):1004-1013. doi: 10.1016/S1473-3099(20)30475-8.

2020

The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization.
Badizadegan K, Goodson JL, Rota PA, Thompson KM. Expert Rev Vaccines. 2020;19(2):175–194. doi: 10.1080/14760584.2020.1732215.

Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR, Bennett SD, Estivariz CF, et al. PLoS Med. 2020;17(3):e1003071. doi: 10.1371/journal.pmed.1003071.

Recent setbacks in measles elimination: The importance of investing in innovations for immunizations.
Goodson JL. Pan Afr Med J. 2020;35(Suppl 1):15. doi: 10.11604/pamj.supp.2020.35.1.21740.

Progress toward rubella elimination — Western Pacific Region, 2000–2019.
Knapp JK, Mariano KM, Pastore R, et al. MMWR Morb Mortal Wkly Rep. 2020;69(24):744–750. doi: 10.15585/mmwr.mm6924a4.

The African Region early experience with structures for the verification of measles elimination — A review.
Masresha B, Luce R, Tanifum P, Lebo E, Dosseh A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):1. doi: 10.11604/pamj.supp.2020.35.1.19061.

Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717­–1725. doi: 10.4269/ajtmh.20-0112.

The epidemiology of rubella, 2007–2018: An ecological analysis of surveillance data.
Patel MK, Antoni S, Danovaro-Holliday MC, et al. Lancet Glob Health. 2020;8(11):e1399-e1407. doi: 10.1016/S2214-109X(20)30320-X.

A microneedle patch for measles and rubella vaccination: A game changer for achieving elimination.
Prausnitz MR, Goodson JL, Rota PA, Orenstein WA. Curr Opin Virol. 2020;41:68–76. doi: 10.1016/j.coviro.2020.05.005.

2019

Successes and challenges for preventing measles, mumps and rubella by vaccination.
Bankamp B, Hickman C, Icenogle JP, Rota PA. Curr Opin Virol. 2019;34:110–116. doi: 10.1016/j.coviro.2019.01.002.

Genetic characterization of measles and rubella viruses detected through global measles and rubella elimination surveillance, 2016­–2018.
Brown KE, Rota PA, Goodson JL, et al. MMWR Morb Mortal Wkly Rep. 2019;68(26):587-591. doi: 10.15585/mmwr.mm6826a3.

Accelerating measles and rubella elimination through research and innovation — Findings from the Measles & Rubella Initiative research prioritization process, 2016.
Grant GB, Masresha BG, Moss WJ, et al. Vaccine. 2019;37(38):5754–5761. doi: 10.1016/j.vaccine.2019.01.081.

Progress toward rubella and congenital rubella syndrome control and elimination — Worldwide, 2000–2018.
Grant GB, Desai S, Dumolard L, Kretsinger K, Reef SE. MMWR Morb Mortal Wkly Rep. 2019;68(39):855–859. doi: 10.15585/mmwr.mm6839a5.

Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL, Grant GB, Moss WJ, et al. Vaccine. 2019;37(38): 5745–5753. doi: 10.1016/j.vaccine.2019.02.058.

Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017.
Moro PL, Arana J, Marquez PL, et al. Vaccine. 2019;37(28):3730–3734. doi: 10.1016/j.vaccine.2019.04.088.

Assessment of economic burden of concurrent measles and rubella outbreaks, Romania, 2011–2012.
Njau J, Janta D, Stanescu A, et al. Emerg Infect Dis. 2019;25(6):1101-1109. doi: 10.3201/eid2506.180339.

Selection From Previous Years

Progress and challenges in measles and rubella elimination in the WHO European Region.
Datta SS, O'Connor PM, Jankovic D, et al. Vaccine. 2018;36(36):5408–5415. doi: 10.1016/j.vaccine.2017.06.042.

Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
Subaiya S, Tabu C, N'ganga J, et al. PLoS One. 2018;13(7):e0199786. doi: 10.1371/journal.pone.0199786.

Rubella vaccine: A tale of appropriate caution and remarkable success.
Zimmerman LA, Reef SE, Orenstein WA. JAMA Pediatr. 2018;172(1):95–96. doi: 10.1001/jamapediatrics.2017.4178.